Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akintunde Akinleye

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Hematology & Oncology|September 7, 2019
Immune checkpoint inhibitors of PD-L1 as cancer therapeuticsAkintunde Akinleye, Zoaib Rasool
Cureus|July 19, 2024
A Case Report on Breast Cancer Following Mantle Radiation for Hodgkin Lymphoma: Screening and ManagementYasmeen Mansour, Akintunde Akinleye
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2014
Ibrutinib and indolent B-cell lymphomasAkintunde Akinleye, Muhammad Furqan, Oluwaseyi Adekunle
Journal of Hematology & Oncology|May 18, 2013
Novel agents for chronic lymphocytic leukemiaMei Wu, Akintunde Akinleye, Xiongpeng Zhu
Journal of Hematology & Oncology|April 17, 2013
MEK and the inhibitors: from bench to bedsideAkintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, et al.
Journal of Hematology & Oncology|August 21, 2013
Ibrutinib and novel BTK inhibitors in clinical developmentAkintunde Akinleye, Yamei Chen, Nikhil Mukhi, et al.
Oncotarget|September 16, 2015
Novel agents for advanced pancreatic cancerAkintunde Akinleye, Chaitanya Iragavarapu, Muhammad Furqan, et al.
Journal of Hematology & Oncology|November 23, 2013
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeuticsAkintunde Akinleye, Parthu Avvaru, Muhammad Furqan, et al.
Journal of Hematology & Oncology|December 7, 2013
STAT inhibitors for cancer therapyMuhammad Furqan, Akintunde Akinleye, Nikhil Mukhi, et al.
Journal of Hematology & Oncology|April 19, 2015
Novel ALK inhibitors in clinical use and developmentChaitanya Iragavarapu, Milaim Mustafa, Akintunde Akinleye, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Hematology & Oncology|September 7, 2019
Immune checkpoint inhibitors of PD-L1 as cancer therapeuticsAkintunde Akinleye, Zoaib Rasool
Cureus|July 19, 2024
A Case Report on Breast Cancer Following Mantle Radiation for Hodgkin Lymphoma: Screening and ManagementYasmeen Mansour, Akintunde Akinleye
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2014
Ibrutinib and indolent B-cell lymphomasAkintunde Akinleye, Muhammad Furqan, Oluwaseyi Adekunle
Journal of Hematology & Oncology|May 18, 2013
Novel agents for chronic lymphocytic leukemiaMei Wu, Akintunde Akinleye, Xiongpeng Zhu
Journal of Hematology & Oncology|April 17, 2013
MEK and the inhibitors: from bench to bedsideAkintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, et al.
Journal of Hematology & Oncology|August 21, 2013
Ibrutinib and novel BTK inhibitors in clinical developmentAkintunde Akinleye, Yamei Chen, Nikhil Mukhi, et al.
Oncotarget|September 16, 2015
Novel agents for advanced pancreatic cancerAkintunde Akinleye, Chaitanya Iragavarapu, Muhammad Furqan, et al.
Journal of Hematology & Oncology|November 23, 2013
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeuticsAkintunde Akinleye, Parthu Avvaru, Muhammad Furqan, et al.
Journal of Hematology & Oncology|December 7, 2013
STAT inhibitors for cancer therapyMuhammad Furqan, Akintunde Akinleye, Nikhil Mukhi, et al.
Journal of Hematology & Oncology|April 19, 2015
Novel ALK inhibitors in clinical use and developmentChaitanya Iragavarapu, Milaim Mustafa, Akintunde Akinleye, et al.
Pageof 2